Lenvatinib Mesylate CAS 857890-39-2 Su'ega 98.0~102.0% Falegaosimea
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates ma maualuga mama
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igoa Vailaau | Lenvatinib Mesylate |
Synonyms | 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima |
Numera CAS | 857890-39-2 |
CAT Numera | RF-PI1975 |
Tulaga Fa'asoa | I Fa'atauga, Oloa Fua e O'o i Tone |
Fuafua mole | C21H19N4O4Cl.CH4O3S |
Molecular Weight | 522.96 |
Fa'ailoga | Ruifu Chemical |
Aitema | Fa'amatalaga |
Fa'aaliga | Pa'epa'e i le Pa'epa'e Pa'epa'e po'o tioata |
Fa'ailoaga | Saunia e IR;E ala i le UV;Saunia e HPLC |
Solubility | E Suavai Teisi i le Vai, E le mafai ona solu ile Ethanol |
Lisi Lisi | 228.0~230.0 ℃ |
Suavai (KF) | <1.00% |
Toega i luga o le mumu | <0.10% |
Metala mamafa | <20ppm |
Mea Fa'atatau | |
So'o se Fa'aleaga Ta'itasi | <0.50% |
Aofa'i Fa'aleaga | <1.00% |
Su'ega / Su'esu'ega Metotia | 98.0~102.0% (Fa'avae HPLC ile Fa'amago) |
To'atele Tele | 0.40gm/ml~0.60gm/ml |
Tulaga Su'ega | Pisinisi Tulaga |
Fa'aoga | API |
afifi: Fagu, ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau
Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu
Lenvatinib Mesylate (CAS: 857890-39-2) o se faʻaoga tautala ma le tele-faʻaogaina o le inhibitor VEGFR1-3, FGFR1-4, PDGFR, KIT, ma RET, faʻatasi ai ma gaioiga faʻamalosi malosi.O le Lenvatinib Mesylate o se fa'atosina o le tyrosine kinase (RTK) e iai le filifiliga mo le VEGFR2.O lo'o fa'aalia ai le gaioiga antineoplastic, ma ua fa'ailoa mai mo le togafitia o tagata mama'i i le fa'alotoifale faifaipea po'o metastatic, alualu i luma, radioactive iodine (RAI) -refractory differentiated thyroid cancer.Lenvatinib Mesylate na faʻamaonia muamua e le US Food and Drug Administration (FDA) ia Feb 13, 2015, ona faʻamaonia lea e Pharmaceuticals and Medical Devices Agency of Japan (PMDA) i le Mati 26, 2015, ma faʻamaonia e le European Medicine Agency (EMA) i luga. Me 28, 2015. Na atiina ae ma maketiina o Lenvima® e Eisai.O le Lenvatinib Mesylate o se fa'amalosaga tele o le tyrosine kinase o lo'o fa'aogaina fa'atasi ma se faiga fa'amaufa'ailoga fa'apitoa e fa'alavelaveina ai gaioiga kinase o le fa'atupuina o le endothelial vascular (VEGF), fa'aopoopo i isi kinases tyrosine e feso'ota'i proangiogenic ma oncogenic e manatu e a'afia i le fa'atuputeleina o le tuma. .O lo'o fa'ailoa mai mo le togafitiga o le fa'asolosolo fa'asolosolo o le radioiodine-refractory differentiated thyroid cancer.Lenvimao lo'o fa'aaogaina e ia lava e togafitia ai le kanesa o thyroid eseese (DTC), o se ituaiga o kanesa o lauroid e le toe mafai ona togafitia i le iodine radioactive ma o lo'o aga'i i luma.LENVIMA e fa'aoga fa'atasi ma se isi vaila'au e ta'ua o le everolimus e togafitia ai tagata matutua o lo'o maua i se ituaiga o kanesa fatuga'o e ta'ua o le advanced renal cell carcinoma (RCC) pe a mae'a le tasi togafitiga ma se isi vaila'au e puipuia ai le kanesa.